Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the ...

The article " Regeneron: Is It the Perfect Biotech Stock for Value and Growth? " first appeared on MarketBeat.

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the Zacks ...

Libtayo's year 2024 sales rose 40% YoY to $ ... Collaboration revenue from Sanofi for 2024 rose to $3.924 billion, up from $3.127 billion. The Board of Directors initiated its first dividend ...

They pointed to "dramatically improved" survival outcomes with immunotherapy, and objective response rates of 44% to 60% with cemiplimab (Libtayo ... and Sanofi SA, and grant funding from Novartis ...